Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy ; volume:13 ; number:3 ; year:2020 ; pages:1483-1489
Case reports in oncology ; 13, Heft 3 (2020), 1483-1489
- Creator
-
Hearon, Bernard F.
Redelman, Kyle N.
Elhomsy, Georges C.
Moore, Jr., Dennis F.
- DOI
-
10.1159/000512013
- URN
-
urn:nbn:de:101:1-2021011323241888420138
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:25 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hearon, Bernard F.
- Redelman, Kyle N.
- Elhomsy, Georges C.
- Moore, Jr., Dennis F.
Other Objects (12)
Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma
ADAM10 mediates malignant pleural mesothelioma invasiveness
Early detection of malignant pleural mesothelioma
KRAS signaling in malignant pleural mesothelioma
Molecular biological analysis of malignant pleural mesothelioma
Genomic Landscape of Pleural Mesothelioma and Therapeutic Aftermaths
Genomic landscape of pleural and peritoneal mesothelioma tumours
Correlation between pleural fluid cytology and magnitude of pleural invasion in patients with malignant pleural mesothelioma
Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma
Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition
GAS5 long non-coding RNA in malignant pleural mesothelioma
Metabolic rewiring and redox alterations in malignant pleural mesothelioma
Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma
ADAM10 mediates malignant pleural mesothelioma invasiveness
Early detection of malignant pleural mesothelioma
KRAS signaling in malignant pleural mesothelioma
Molecular biological analysis of malignant pleural mesothelioma
Genomic Landscape of Pleural Mesothelioma and Therapeutic Aftermaths
Genomic landscape of pleural and peritoneal mesothelioma tumours
Correlation between pleural fluid cytology and magnitude of pleural invasion in patients with malignant pleural mesothelioma
Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma
Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition
GAS5 long non-coding RNA in malignant pleural mesothelioma
Metabolic rewiring and redox alterations in malignant pleural mesothelioma
Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma
ADAM10 mediates malignant pleural mesothelioma invasiveness
Early detection of malignant pleural mesothelioma
KRAS signaling in malignant pleural mesothelioma
Molecular biological analysis of malignant pleural mesothelioma
Genomic Landscape of Pleural Mesothelioma and Therapeutic Aftermaths
Genomic landscape of pleural and peritoneal mesothelioma tumours
Correlation between pleural fluid cytology and magnitude of pleural invasion in patients with malignant pleural mesothelioma
Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma
Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition
GAS5 long non-coding RNA in malignant pleural mesothelioma